【摘要】 目的:通过检测凋亡抑制蛋白Livin在非小细胞肺癌患者围手术期血清中的含量,分析其围手术期变化趋势,探讨Livin在非小细胞肺癌诊断、分级、预后判断的临床意义。方法:采用酶联免疫吸附法(ELISA)对40例非小细胞肺癌患者术前、术后血清中Livin的表达水平及20例正常健康人血清Livin水平进行检测。结果:非小细胞肺癌患者血清Livin水平明显高于健康对照组;术前(中位数526.49 ng/L,四分位间距357.93～825.57 ng/L)、术后(中位数286.49 ng/L,四分位间距157.93～515.57 ng/L),两组间存在统计学差异(P<0.05);血清Livin平均水平与非小细胞肺癌临床病理学的关系:Ⅰ、Ⅱ期(中位数326.49 ng/L,四分位间距201.54～623.19 ng/L)与Ⅲ期(中位数586.31 ng/L,四分位间距411.79～965.34 ng/L)之间存在统计学差异(P<0.05);肿瘤淋巴结转移11例(中位数562.03 ng/L,四分位间距382.64～982.61 ng/L)与无淋巴结转移29例(中位数344.59 ng/L,四分位间距167.27～646.20 ng/L)之间存在明显差异(P<0.05);组织学高、中、低分化三组间无明显差异(P>0.05)。结论:Livin作为一种新的凋亡抑制蛋白,对非小细胞肺癌诊断、分期具有一定的临床价值。更多还原

【Abstract】 AIM: To detect the inhibitor of apoptosis protein Livin in non-small cell lung cancer patients with perioperative serum levels were analyzed trends in perioperative period to explore the Livin in non-small cell lung cancer diagnosis,classification and prognosis of clinical significance.METHODS: Enzyme-linked immunosorbent assay(ELISA) of 40 patients with non-small cell lung cancer patients before surgery,the serum levels of Livin expression and 20 cases of normal healthy human serum levels of Livin were detected.RESULTS: Non-small cell lung cancer patients was significantly higher than the level of serum Livin healthy control group.Before surgery(median 526.49 ng/L,quartile 357.93-825.57 ng/L),postoperative(median 286.49 ng/L,quartile 157.93-515.57 ng/L),there was significant difference between the two groups(P<0.05).Livin the average level of serum with non-small cell lung cancer the relationship between pathology: Ⅰ,Ⅱ period(median 326.49 ng/L,quartile 201.54-623.19 ng/L) and stage Ⅲ(median 586.31 ng/L,quartile 411.79-965.34 ng/L) statistically significant difference between(P<0.05);tumor lymph node metastasis in 11 cases(median 562.03 ng/L,quartile 382.64-982.61 ng/L) and the 29 cases without lymph node metastasis(median 344.59 ng/L,quartile 167.27-646.20 ng/L) significant difference between(P<0.05);organization credits of: high,medium,poorly differentiated among the three groups without significant differences(P>0.05).CONCLUSION: Livin as a new inhibitor of apoptosis protein in non-small cell lung cancer diagnosis,staging has some clinical value.更多还原